BG

Bunge Limited Receives High Participation in Exchange Offers

Bunge Limited Finance Corp. has released its results of early participation in exchange offers and consent solicitations. As of September 20, 2024, the company received consents from eligible holders representing 96.5% in principal amount of 2.000% notes due 2026 and 3.200% notes due 2031, voting as one class, and 97.6% in principal amount of 4.900% notes due 2027 and 5.250% notes due 2032, voting as one class.

The principal amounts of existing Viterra notes validly tendered and not validly withdrawn as of the early tender date are as follows: 2.000% notes due 2026: $566,348,000 4.900% notes due 2027: $436,993,000 3.200% notes due 2031: $591,131,000 5.250% notes due 2032: $295,000,000

These figures indicate a high level of participation in the exchange offers and consent solicitations.

Eligible holders who validly tender their existing Viterra notes at or prior to the early tender date, deliver their related consent, and beneficially own such existing Viterra notes at the expiration date will be eligible to receive the total exchange consideration, including a consent payment of $1.00 in cash.

The settlement date for the exchange offers and consent solicitations is expected to be within two business days after the expiration date, and the company may extend the expiration date if the consummation of Bunge’s pending acquisition of Viterra is not anticipated to occur by the then-anticipated settlement date.

Bunge Limited Finance Corp. engaged BofA Securities, Inc. and J.P. Morgan Securities LLC as lead dealer managers and solicitation agents for the exchange offers and consent solicitations.

Today the company's shares have moved -1.1% to a price of $97.74. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS